Kornimate/medical-research-clean huggingface dataset:
phase ib/ii study of nrt combined with radiotherapy for advanced hcc

Conditions: HCC

Summary: the study herein successfully developed a new immunotherapeutic approach combined with radiotherapy, and tried to proved it to be more effective and safe.

hepatocellular carcinoma (hcc) is the fifth most common cancer and the third leading cause of cancer-related death worldwide. the resection rate for hcc is approximately 10%-30% and the overall prognosis is very poor with a 5-year survival rate of 5%-6%. the recurrence rate is high after radical resection. in addition to surgery, radiofrequency ablation, transcatheter arterial chemoembolization (tace), microwave ablation, cryoablation, radioactive seeds implantation, high-intensity-focused ultrasound, radiation therapy, chemotherapy and targeted drugs are available for patients with unresectable tumors; however, the efficacy of these treatments are limited and long-term prognosis in the patients is still poor. moreover, due to serious side effects induced by treatments such as tace, chemotherapy and targeted drugs, it may not be possible for patients to continue receiving these therapies. the study herein successfully developed a new immunotherapeutic approach combined with radiotherapy, and tried to proved it to be more effective and safe.

Eligibility criteria:
inclusion criteria: 1. female or male aged 18 years and over, but no more than 75 years; 2. histologic or cytologic confirmation of advanced hepatocellular carcinoma; 3. patients with measurable lesions but can not be treated with surgery; 4. patients with two or over measurable lesions; 5. ecog≤0-2, child-pugh a-b; 6. patients had not received systemic venous chemotherapy ever before; 7. hematology index; 8. neutrophile granulocyte greater than 1.5×10\^9/l; 9. hemoglobin greater than 10g/dl; 10. platelet greater than 90×10\^9/l; 11. biochemical index 12. serum bilirubin not greater than 1.5x upper limit of reference range （uln） 13. alt or ast not greater than 1.5x uln 14. creatinine clearance no less than 60ml/min; 15. negative pregnancy test for women of childbearing potential; 16. provision of informed consent; 17. be able to follow the research program and follow up process; 18. expected survival time 3 months or more. exclusion criteria: 1. chemotherapy with experimental drug within 3 months before the start of study therapy; 2. have at least another primary malignant tumor; 3. active infection with bacterial or fungal infection; 4. patients with hiv infection, hcv infection, serious coronary artery disease or asthma, serious cerebrovascular disease or other diseases that the researchers think can not be entered into the group; 5. women who are pregnant or breast feeding; 6. drug abuse, clinical or psychological or social factors which will influence the informed. consent or the study implementation; 7. may be allergic to immunotherapy; 8. radiotherapy and immunotherapy may not be implemented due to social or geographical factors; 9. weight loss greater 10% within 6 weeks before the start of study therapy; 10. influence the safety or compliance of the patients.

Keywords: hcc nrt tomo radiotherapy
foot muscles training in sclerosis

Conditions: Multiple Sclerosis; Muscle Weakness; Training Group, Sensitivity

Summary: the study tries to assess the efficacy of an 8-week ifm training programme on stability in patients diagnosed with multiple sclerosis


Eligibility criteria:
inclusion criteria: * patients with moderate neurological disability as scored by the expanded disability status scale (edss), ranging from 3.0 to 6.0 exclusion criteria: * cognitive disturbances that could affect the performance of any of the tests or questionnaires included in the study * diagnosis of visual or vestibular disorders that could affect patient stability * change in multiple sclerosis-specific medication in the 2 months prior to the start of the study * acute relapse in the 2 months prior to the start of the study * traumatologic or orthopaedic disorders that could negatively affect balance.
turkish adaptation, validity and reliability study of the athlete disability index questionnaire

Conditions: Low Back Pain; Disability; Athlete; Sport

Summary: this survey study aims to analyze the cultural adaptation, validity, and reliability of a scale originally in english and currently being translated into turkish, which allows athletes with low back pain to assess their functional disabilities in sports and exercise activities as well as their disabilities in daily living activities. athletes with low back pain will be asked to fill out 3 questionnaires.

in the study, firstly, the translation of the athlete disability index questionnaire (adi) into the target language, comparison of the two translated versions of the scale, back translation of the preliminary version, synthesis, pilot test of the pre-final version and psychometric test studies will be carried out by 3 independent translators and 2 linguists in 6 stages. then, 120 athletes with low back pain will be asked to fill out the adi, roland morris disability questionnaire (rmdq) and oswestry low back pain disability index (odi). 7 days later, the adi will be filled out again by 60 athletes. after the surveys are completed, the structural validity of the scale will be tested, and reliability will be measured by performing test-retest reliability and internal consistency analyses.

Eligibility criteria:
inclusion criteria: * low back pain that has persisted for at least 6 weeks * pain that worsens with changes in posture, movement, or physical activity * elite athletes with a regular training/match schedule of more than 10 hours per week exclusion criteria: * not knowing turkish * acute inflammatory conditions * acute musculoskeletal trauma * long-term corticosteroid use
master allergen child nutrition. reintroduction of small doses

Conditions: Food Allergies

Summary: reintroduction of small doses of food in allergic children to lightening the elimination diet.

in four groups of allergic children (peanuts, wheat , milk and egg), a reintroduction of 4 small increasing doses of allergen is carried out progressively double-blind placebo- cons , randomized, during a hospitalization. the procedure for reintroduction of small doses (mpd) is stopped at the appearance of intolerance (in taking a dose of allergen or placebo) defined by the onset of allergic symptoms or objective severe abdominal pain within 45 minutes of taking.

Eligibility criteria:
inclusion criteria: * allergic children 1 and 16 years for peanut, egg and wheat. so, for milk between 9 months and 16 years. * accurate diagnostic * allergic react rapidly and acute exclusion criteria: * severe disease
a phase ii trial to assess the safety and immunogenicity of dna priming administered by the id zetajet® with or without id derma vax™ electroporation followed by im mva boosting in healthy volunteers in tanzania and mozambique

Conditions: Vaccines; HIV; Safety; Immunogenicity

Summary: electroporation will increase the efficiency of dna priming in terms of immune responses and will lead to a dose sparing dna vaccine regimen. furthermore increased dna vaccine concentration will reduce the number of shots necessary to deliver the full dose and induce comparable immune responses as with lower dna vaccine concentrations.


Eligibility criteria:
inclusion criteria: * willing to undergo counselling and hiv testing. * have a negative antigen/antibody elisa for hiv infection. * able to give informed consent. * basic abilities to read and write. * satisfactory completion of an assessment of understanding prior to enrolment defined as 90% correct answers after three opportunities to take test. * resident of the region where the study is taking place. * at low risk of hiv infection. * verbal assurances for adequate birth control measures. * healthy as evidenced by clinical and laboratory measures exclusion criteria: * at risk of hiv infection. * active tuberculosis. * a history of immunodeficiency, ongoing medical and/or psychiatric condition and/or chronic illness requiring continuous or frequent medical intervention. * autoimmune disease. * hives and severe eczema. * substance abuse problems. * history of grand-mal epilepsy. * received blood or blood products or immunoglobulins in the past 3 months. * receiving immunosuppressive therapy such as systemic corticosteroids or cancer chemotherapy. * use of experimental therapeutic agents within 30 days of study entry. * history of cardiac disease
effect of ablation of persistent atrial fibrillation on cognitive function in individuals with mild cognitive impairment

Conditions: Mild Cognitive Impairment; Persistent Atrial Fibrillation

Summary: the goal of this clinical trial is to evaluate the effect of catheter ablation of persistent atrial fibrillation on cognitive function in patients with mild cognitive impairment. participants will be randomized into antiarrhythmic drugs alone or atrial fibrillation ablation + antiarrhythmic drugs.


Eligibility criteria:
inclusion criteria: * patients aged 60 to 85 years * persistent atrial fibrillation * patients with an indication for cardiac rhythm control. * montreal cognitive assessment score between 18 and 25 points corresponding to mild cognitive impairment * free subject, not under temporary or permanent guardianship and not subject to subordination * subject understanding and accepting the constraints of the study * patient covered by french national health insurance or benefiting from it through a third party * subject has given written consent to the study after having received clear and complete information exclusion criteria: * impossibility to perform the neuropsychological evaluation (communication problems such as hearing loss or aphasia, language barrier) * history of clinical stroke * presence of a bruit at carotid auscultation or history of severe carotid stenosis * history or suspicion of neurodegenerative disease (parkinson's disease, alzheimer's disease, huntington's disease and amyotrophic lateral sclerosis...), bipolar disorder, schizophrenia, severe depression or amyloidosis * patient with history of previous atrial fibrillation ablation * patient undergoing flutter ablation or atrial tachycardia ablation (not atrial fibrillation ablation) * contraindication to atrial fibrillation ablation (intracardiac thrombus, severe pulmonary hypertension, mechanical mitral valve prosthesis or contraindication to anticoagulation,...) * contraindication to antiarrhythmic drugs, or to implantable cardiac monitor * patient with very advanced persistent atrial fibrillation, i.e., for more than 3 years or with a left atrial diameter \>60 mm in parasternal long axis section or a left atrial volume \> 48ml/m2 in echocardiography * subject with a life expectancy of less than 24 months at study enrolment * inability to consent * persons benefiting from a reinforced protection, namely minors, persons deprived of liberty by a judicial or administrative decision, adults under legal protection, and finally patients in emergency situations * pregnant or breastfeeding women, women at age to procreate and not using effective contraception (hormonal/barrier: oral, parenteral, percutaneous implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total ovariectomy)
intraoperative radiation therapy for locally advanced or recurrent abdomino-pelvic solid tumors with the civasheet

Conditions: Abdominal Malignancy; Pelvic Malignancy

Summary: this study is a pilot study of the civasheet, a new type of intraoperative radiation therapy (iort) device that offers several advantages over existing techniques of performing iort. the civasheet device in this study is already approved by the fda and is not an experimental device. this study will allow us to determine how feasible it is to implant the civasheet into patients undergoing surgery for abdominal and pelvic tumors, and assess any possible side effects of the device. this study, if successful, may allow us to offer the civasheet more widely as treatment option to future patients.


Eligibility criteria:
inclusion criteria: * histologic, cytologic, or radiologically evidence of locally advanced, residual or recurrent solid malignancy of the abdomen or pelvis requiring surgical resection * maximum projected treatment length 15cm and width 5cm, which are the dimensions of the largest available civasheet * medically fit and willing to undergo resection of disease * age ≥ 18 years * ecog performance status 0, 1, or 2 * anc ≥ 1.5 cells/mm3, plt≥100,000/mm3, pt/aptt within normal limits at time of surgery * life expectancy, in the clinician's judgment, greater than 1 year. exclusion criteria: * women who are pregnant * women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy after the receipt of brachytherapy. male subjects must also agree to use effective contraception during the treatment period and until 1 year after the completion of brachytherapy * patients with any concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study. * patients who, in the investigator's judgment, are unwilling or unable to consent to and return for recommended post-treatment scans as outlined in this study. * patients on concurrent anti-cancer therapy, unless specifically agreed to by the patient's medical oncologist and consenting professional. * patients with contraindications to general anesthesia, as determined by the treating physician or surgeon

Keywords: low dose rate brachytherapy civasheet 16-605
the evaluating multidisciplinary bone marrow failure care in bone marrow failure and related disorders.

Conditions: Bone Marrow Failure Syndrome; Aplastic Anemia

Summary: this is a prospective hybrid implementation-effectiveness study of a model of care for patients with bone marrow failure syndromes and inherited predisposition to haematological malignancy that includes comprehensive diagnostic genomic evaluation, multidisciplinary case review, provision of clinical care including from clinical haematologists, medical geneticists and genetic counsellors.

the inherited bone marrow disorders (ibmd) comprise both the traditional inherited bone marrow failure syndromes (bmfs) and the more recently described entity of germline predisposition to haematological malignancy. patients with ibmd often present highly complex health issues that are unique and not commonly encountered. as a consequence, clinicians may feel less confident in managing these unique issues given their lack of frequent exposure to this patient group. recent advances in genomics have resulted in more accurate diagnosis of ibmd and their subtyping and have resulted in a rapidly evolving field with multiple opportunities to improve patient outcomes. stage 1 of this study evaluated and quantified the current challenges faced by 3 stakeholder groups, patients with ibmd, patient advocates and nationally, clinicians who care for ibmd patients. the results demonstrated that the challenges described in stage 1 may be overcome by instigating a multidisciplinary approach to care for bmf patients. interventions designed to address the challenges identified in stage 1 form the model of multidisciplinary care to be implemented in the peter maccallum cancer centre/ royal melbourne hospital clinic. the model of care involves: 1. provide access to genetic testing with expert result interpretation 2. presentation of clinical information and relevant investigations (including genetic) at a multidisciplinary team meeting involving haematologists, molecular haematopathologists, clinical genetics, genetic counsellors, scientists and specialised nurses. 3. provision of a suggested care plan to clinician 4. genetic counselling and provision of written disease specific information including details of suggested care plan to patient 5. genetic counselling and provision of written information and access to testing for at risk family members 6. dedicated team focused on many individually rare diseases with a demonstrated focus on provision of comprehensive care 7. opportunity to participate in local and international research the embrace study will focus on evaluating the model of care.

Eligibility criteria:
inclusion criteria: patients must meet all the following criteria for study entry: 1. age \> or = 18 years at enrolment 2. able to give informed consent (or responsible family member able to give informed consent) 3. patient is receiving care under the institutional guidelines/stream model of care exclusion criteria: 1. patient not eligible for management under the model of care
arrhythmia identification in syncope patients: epatch® versus 24h holter

Conditions: Arrythmia; Syncope

Summary: this study is a multi-center, prospective, randomized, unblinded, two-arm study to assess if 7-days of cardiac monitoring using the epatch holter results in identification of more clinically actionable arrythmia for patients with symptoms of syncope than standard 24 hour holter monitoring.

this study is a multi-center, prospective, randomized, unblinded, two-arm study to assess if 7-days of cardiac monitoring using the epatch holter results in identification of more clinically actionable arrythmia for patients with symptoms of syncope than standard 24 hour holter monitoring. approximately 256 adult subjects with symptoms of syncope will be randomized 1:1 to wear either the philips epatch extended wear holter (7 day) or standard wear holter (24 hours). randomization will be balanced for gender.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old 2. recommended for ambulatory cardiac holter monitoring due to symptoms of syncope 3. able to comply with continuous ecg monitoring for up to 7 days 4. able and willing to replace the patch electrode at home 5. capable of providing voluntary informed consent and mentally and physically willing and able to be compliant with the protocol, including the follow-up visit(s) exclusion criteria: 1. patient with chronic atrial fibrillation (af) 2. patient with implanted pacemaker/defibrillator 3. patient with known allergy to adhesive materials and/or hydrogel 4. patient with broken, damaged, or irritated skin where ecg patch will be placed

Keywords: clinically actionable arrhythmia symptoms of syncope
outcome of small pupil phacotrabeculectomy in persons with glaucoma and cataract

Conditions: Glaucoma; Cataract

Summary: small pupils are not uncommon in situations requiring surgical intervention for glaucoma and cataract. inadequate binocular view during combined trabeculaectomy and glaucoma surgery needs to be overcome by additional iris manupulations to dilate the pupils which increase the liklihood of inflammation, inraocular pressure rise after surgery and enhnced liklihood of failure of glaucoma surgery. the proposed trial is an observational study to analyse post operative outcome of eyes undrgoing trabeculectomy and phacoemulsification with intraocular lens implantation with small pupils in persons with glaucoma coexisting with cataract.

small pupils are not uncommon in situations requiring surgical intervention for glaucoma and cataract. inadequate binocular view during combined trabeculaectomy and glaucoma surgery needs to be overcome by additional iris manupulations to dilate the pupils which increase the liklihood of inflammation, inraocular pressure rise after surgery and enhnced liklihood of failure of glaucoma surgery. the proposed trial is an observational study to analyse post operative outcome of eyes undrgoing trabeculectomy and phacoemulsification with intraocular lens implantation with small pupils in persons with glaucoma coexisting with cataract

Eligibility criteria:
inclusion criteria: * individuals with visually significant cataracts and medically uncontrolled primary open angle, angle clsoure, exfolaitive glaucoma exclusion criteria: * complicated catracts and secondary glaucoma

Keywords: glaucoma catarat small pupils
trial on vascular inflammation in atopic dermatitis

Conditions: Atopic Dermatitis; Vascular Inflammation; Coronary Atherosclerosis

Summary: a total of 30 subjects with moderate to severe atopic dermatitis. thirty subjects without ad matched for sex, age and coronary artery disease risk factor with the ad subjects will also be included. all subjects will undergo the following imaging procedures: a 18fdg-pet to quantify vascular inflammation in the ascending aorta and carotids and a mdct to calculate the agatston score. skin and blood biomarkers will also be assessed.


Eligibility criteria:
main inclusion criteria: * men or women * 18 years of age or older at time of consent. * for ad subjects only: confirmed clinical diagnosis of active ad according to hanifin and rajka criteria, bsa, easi and iga. * for ad subjects only: diagnosis of atopic dermatitis for at least 5 years. * women of childbearing potential is willing to use effective contraceptive method. * women of childbearing potential must have a negative urine pregnancy test. main exclusion criteria: * has known cardiovascular arterial disease, a pacemaker, psoriasis, uncontrolled diabetes. * presence of an unstable co-morbidity that could have an effect on vascular inflammation. * heart rate restriction for patients with asthma or copd. * use of any topical medication for atopic dermatitis on the site to be biopsied. * use of systemic treatments for atopic dermatitis. * use of phototherapy, tanning booth or other ultraviolet light sources. * use of biologics. * use of experimental medications.

Keywords: atopic dermatitis vascular inflammation coronary atherosclerosis ascending aorta pet scan
pneumonia and empyema in emergency departments in children

Conditions: Pneumonia; Pleural Effusion

Summary: describe the epidemiology of hospitalized pediatric pneumonia and pneumonia with pleural effusion: frequency, clinical and biological characteristics, responsible bacteria and pneumococcus place, antibiotic resistance, treatment, vaccine status.

the pneumonia observatory began in june 2009 and has included more than 15,000 children with pneumonia or pneumonia with pleural effusion (hospitalized or not) until may 2019. this study led to the publication of many articles in international peer-reviewed journals. since june 2019, the scientific committee of the study met at the espid congress has decided to include only hospitalized patients. this amendment is justified for three reasons: * change in criteria for diagnosing pneumonia with increasing use of chest ultrasound * logistical aspects and workload of investigating centers too important * long-term impact of pneumococcal vaccine 13-valent especially marked for the most severe cases in this context, the purpose of this amended study is to enroll only the most severe cases of pneumonia, i.e. requiring hospitalization, in icu or not. since this study began in 2009, we have already enrolled hospitalized cases, we will have a baseline prior to the introduction of third-generation pcvs (pneumococcal conjugate vaccines) and we will be able to continue monitoring with data since 2009.

Eligibility criteria:
inclusion criteria: * ages between 1 month and 15 years * presence of parenchymatous condensation and/or pleural effusion on chest x-rays and/or ultrasounds and/or ct scans * fever ≥38.5 °c if age ≥3 months since the onset of symptoms or ≥38 °c if the child is less than 3 months old. * hospitalization exclusion criteria: * refusal of participation by the patient, his or her relative or legal representative (depending on the situation)

Keywords: children pneumococcal conjugate vaccine